Replies to post #755535 on NorthWest Biotherapeutics Inc (NWBO)

[StonkMaster]

Cheers! 

[10baggerz]

You’re currently one of the few people who add new factual information to this board. Please don’t give someone with 10,000+ negative posts the time of day.
THANK YOU FOR YOUR EFFORTS!

[flipper44]

Fairer response. Thanks for all your DD.

[StonkMaster]

Any updates?

[StonkMaster]

Marstacimab approved to treat patients aged 12 years and above (weighing at least 35 kg) with haemophilia A or B

https://www.gov.uk/government/news/marstacimab-approved-to-treat-patients-aged-12-years-and-above-weighing-at-least-35-kg-with-haemophilia-a-or-b?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=1bbf7f18-60c0-4085-aaec-5b31bc7870b6&utm_content=immediately

[StonkMaster]

MHRA approves first UK treatment for Friedreich’s ataxia, omaveloxolone
https://www.gov.uk/government/news/mhra-approves-first-uk-treatment-for-friedreichs-ataxia-omaveloxolone?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=9cc6f06c-33f2-4786-a617-ae30d5815be4&utm_content=immediately

[StonkMaster]

Obecabtagene autoleucel conditionally approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
https://www.gov.uk/government/news/obecabtagene-autoleucel-conditionally-approved-to-treat-adults-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukaemia?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=53b1a825-6711-44f9-8b22-dbcc8597065c&utm_content=immediately

[StonkMaster]

Acoramidis approved to treat wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy
https://www.gov.uk/government/news/acoramidis-approved-to-treat-wild-type-or-variant-transthyretin-amyloidosis-in-adults-with-cardiomyopathy?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=c07db869-54a0-49d6-8c16-70c643cc5aed&utm_content=immediately

[KRISGO]

According to the findings of the TVOP analysis: in 6 business days

I gave a specific date (5/6/25) after which our application would officially be in unprecedented territory. I stand by that date as a point at which I personally would begin to feel worried about how long it was taking (even though, since that time, mRESVIA received approval with an even longer timeline).

[StonkMaster]

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (30 April 2025) approved a new under-the-skin injection version of the cancer therapy, nivolumab (Opdivo), offering a quicker administration option for eligible patients. 
https://www.gov.uk/government/news/mhra-authorises-cancer-treatment-variation-with-an-administration-time-of-3-5-minutes?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=e6df9e2e-1fec-449c-a11f-330fb5ea74c6&utm_content=immediately

[KRISGO]

TVOP, based on your last message, you mentioned that if approval doesn’t happen by May 6th, 2025, the application would be in unprecedented territory. Are you still standing by that timeline, or has anything recent changed your view?

The third quote is from a post on 2/4/25. The timeframe mentioned in it refers to something I mentioned in another post on the same day, in which I gave a specific date (5/6/25) after which our application would officially be in unprecedented territory. I stand by that date as a point at which I personally would begin to feel worried about how long it was taking (even though, since that time, mRESVIA received approval with an even longer timeline).

[StonkMaster]

Tunnel,
What happened?